EUVIMEDEUVIMED entdecken
Crossref

Peripheral T- and B-cell immune signatures associated with response to vedolizumab in ulcerative colitis

Shunsuke Horitani, Anna Horitani, Christopher J Tyler, Makoto Naganuma iD, Peter B Ernst, Davey Smith, Derek R Patel, Brian Behm, Andres Yarur, Jesús Rivera-Nieves iD

Inflammatory Bowel Diseases · 06.11.2026

DOI: 10.1093/ibd/izag242 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 06.11.2026. Verfasst von Shunsuke Horitani und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, University of California San Diego [UCSD], La Jolla, CA, United States. Die Arbeit nennt 26 Literaturangaben. Gefördert von: NIDDK NIH HHS, Veterans Administration Merit, Takeda Pharmaceuticals U.S.A.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aims Vedolizumab (VDZ) blocks integrin α4β7-MAdCAM-1 interactions, limiting leukocyte entry into the gut, yet peripheral-blood immune correlates of clinical response in ulcerative colitis (UC) remain unidentified.

Methods

Peripheral blood mononuclear cells from healthy controls (HCs) and patients with UC, stratified by VDZ exposure and clinical response, were analyzed using mass cytometry (cytometry by time-of-flight). A 38-marker panel enriched for integrins, chemokine receptors, and activation markers was applied. Major immune populations were interrogated using lineage-specific opt-SNE and FlowSOM clustering.

Results

The dataset included 26 HCs, 30 VDZ-naive UC (Nancy index ≥ 2), 8 VDZ-treated non-responders (Nancy index ≥ 2), and 8 VDZ-treated responders (Nancy index <2). No significant differences were detected in myeloid, NK-cell, or TCRγδ+ T-cell compartments. Integrin α4β7+ cells were detected across multiple immune lineages and were enriched in the B-cell compartment. Between-group differences were observed in the CD4+ T-cell and B-cell compartments. VDZ responders showed enrichment of an α4β7+ effector memory CD4+ T-cell subset compared with VDZ-naive UC. In parallel, responders exhibited reduced frequencies of class-switched plasmablast and activated B-cell populations relative to VDZ-naive UC. Integrin-pairing analysis demonstrated that these B-cell populations contained both α4β7+ and α4β1+ cells. In contrast, VDZ non-responders showed enrichment of an α4β7+ atypical-like IgA+ memory B-cell subset relative to responders, VDZ-naive UC, and HCs.

Conclusions

Clinical response and non-response to VDZ in UC are associated with distinct circulating T- and B-cell immune phenotypes. Peripheral-blood immunophenotyping may identify correlates of response and non-response. Prospective studies are needed to determine whether these signatures are predictive before VDZ initiation or reflect pharmacodynamic changes after treatment.

Schlagwörter

Stichwörter der Autor:innen

integrinmass cytometryulcerative colitisvedolizumab

Autor:innen und Institutionen

  • Division of Gastroenterology, University of California San Diego [UCSD], La Jolla, CA, United States.
  • Third Department of Internal Medicine, Division of Gastroenterology and Hepatology, Kansai Medical University, Osaka, Japan.
  • Chiba University-UCSD Center for Mucosal Immunology, Allergy and Vaccines, Chiba, Japan.
  • Chiba University-UCSD Center for Mucosal Immunology, Allergy and Vaccines, La Jolla, CA, United States.
  • Infectious Diseases, University of California San Diego [UCSD], La Jolla, CA, United States.
  • Division of Gastroenterology, University of Virginia, Charlottesville, VA, United States.

ORCID-Profile: Makoto Naganuma, Jesús Rivera-Nieves

Förderung

  • NIDDK NIH HHS
  • Veterans Administration Merit
  • Takeda Pharmaceuticals U.S.A
  • Chiba University-UCSD Center for Mucosal Immunology
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • Chiba University–UCSD Center for Mucosal Immunology

Zitieren

APA

Horitani, S., Horitani, A., Tyler, C. J., Naganuma, M., Ernst, P. B., Smith, D., Patel, D. R., Behm, B., Yarur, A., & Rivera-Nieves, J. (2026). Peripheral T- and B-cell immune signatures associated with response to vedolizumab in ulcerative colitis. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izag242

Vancouver

Horitani S, Horitani A, Tyler CJ, Naganuma M, Ernst PB, Smith D, et al. Peripheral T- and B-cell immune signatures associated with response to vedolizumab in ulcerative colitis. Inflammatory Bowel Diseases. 2026. doi:10.1093/ibd/izag242

BibTeX
@article{Horitani2026,
  author = {Horitani, Shunsuke and Horitani, Anna and Tyler, Christopher J and Naganuma, Makoto and Ernst, Peter B and Smith, Davey and Patel, Derek R and Behm, Brian and Yarur, Andres and Rivera-Nieves, Jesús},
  title = {Peripheral T- and B-cell immune signatures associated with response to vedolizumab in ulcerative colitis},
  journal = {Inflammatory Bowel Diseases},
  year = {2026},
  doi = {10.1093/ibd/izag242}
}
Kostenlos starten →